• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

吸入式抗SARS-CoV-2及其变体的肝素多糖纳米诱饵

Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants.

作者信息

Tu Bin, Wang Huiyuan, An Xinran, Qu Jingkun, Li Qianqian, Gao Yanrong, Shi Mingjie, Qiu Hong, Huang Yongzhuo

机构信息

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

University of Chinese Academy of Sciences, Beijing 100049, China.

出版信息

Acta Pharm Sin B. 2022 Jul;12(7):3187-3194. doi: 10.1016/j.apsb.2022.01.019. Epub 2022 Feb 11.

DOI:10.1016/j.apsb.2022.01.019
PMID:35169535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8830937/
Abstract

The heparin polysaccharide nanoparticles block the interaction between heparan sulfate/S protein and inhibit the infection of both wild-type SARS-CoV-2 pseudovirus and the mutated strains through pulmonary delivery.Image 1.

摘要

肝素多糖纳米颗粒通过肺部给药阻断硫酸乙酰肝素/S蛋白之间的相互作用，并抑制野生型SARS-CoV-2假病毒和突变株的感染。图1。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a44/9293672/f86457112ac2/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a44/9293672/136a27c3e294/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a44/9293672/f5ea033ef8e2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a44/9293672/923d2e5b67fd/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a44/9293672/f86457112ac2/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a44/9293672/136a27c3e294/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a44/9293672/f5ea033ef8e2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a44/9293672/923d2e5b67fd/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a44/9293672/f86457112ac2/gr3.jpg

相似文献

1
Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants.吸入式抗SARS-CoV-2及其变体的肝素多糖纳米诱饵
Acta Pharm Sin B. 2022 Jul;12(7):3187-3194. doi: 10.1016/j.apsb.2022.01.019. Epub 2022 Feb 11.
2
Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants.肝素与来自奥密克戎及其他变体的新冠病毒刺突糖蛋白受体结合域之间的相互作用。
Front Mol Biosci. 2022 Aug 15;9:912887. doi: 10.3389/fmolb.2022.912887. eCollection 2022.
3
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.SARS-CoV-2 感染依赖于细胞表面的肝素硫酸和 ACE2。
Cell. 2020 Nov 12;183(4):1043-1057.e15. doi: 10.1016/j.cell.2020.09.033. Epub 2020 Sep 14.
4
Heparan Sulfate Facilitates Spike Protein-Mediated SARS-CoV-2 Host Cell Invasion and Contributes to Increased Infection of SARS-CoV-2 G614 Mutant and in Lung Cancer.硫酸乙酰肝素促进刺突蛋白介导的SARS-CoV-2宿主细胞侵袭，并导致SARS-CoV-2 G614突变体在肺癌中的感染增加。
Front Mol Biosci. 2021 Jun 11;8:649575. doi: 10.3389/fmolb.2021.649575. eCollection 2021.
5
Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from .槐糖脂硫酸酯抗 SARS-CoV-2 活性研究。
Mar Drugs. 2021 Nov 30;19(12):685. doi: 10.3390/md19120685.
6
PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.PRO-2000 通过干扰刺突-肝素结合发挥抗 SARS-CoV-2 活性。
Antiviral Res. 2023 Sep;217:105700. doi: 10.1016/j.antiviral.2023.105700. Epub 2023 Aug 9.
7
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染依赖于细胞硫酸乙酰肝素和血管紧张素转换酶2（ACE2）。
bioRxiv. 2020 Jul 14:2020.07.14.201616. doi: 10.1101/2020.07.14.201616.
8
Syndecan-4 Is a Key Facilitator of the SARS-CoV-2 Delta Variant's Superior Transmission.Syndecan-4 是 SARS-CoV-2 德尔塔变体高传播性的关键促进因素。
Int J Mol Sci. 2022 Jan 12;23(2):796. doi: 10.3390/ijms23020796.
9
Sulfated liposome-based artificial cell membrane glycocalyx nanodecoys for coronavirus inactivation by membrane fusion.基于硫酸化脂质体的人工细胞膜糖萼纳米诱饵通过膜融合作用灭活冠状病毒
Bioact Mater. 2023 Nov 4;33:1-13. doi: 10.1016/j.bioactmat.2023.10.021. eCollection 2024 Mar.
10
Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions.苏拉明通过与刺突蛋白-肝素硫酸和 ACE2 受体的相互作用结合并抑制 SARS-CoV-2 的感染。
Commun Biol. 2023 Apr 8;6(1):387. doi: 10.1038/s42003-023-04789-z.

引用本文的文献

1
Broad-Spectrum Antiviral Styrene Maleic-Acid Copolymer Lipid Particle Nanodiscs for pH-Responsive Irreversible Virus Inactivation.用于pH响应性不可逆病毒灭活的广谱抗病毒苯乙烯-马来酸共聚物脂质颗粒纳米盘
Biomacromolecules. 2025 Jul 14;26(7):4051-4068. doi: 10.1021/acs.biomac.5c00037. Epub 2025 Jun 10.
2
Defining diverse spike-receptor interactions involved in SARS-CoV-2 entry: Mechanisms and therapeutic opportunities.定义参与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入的多种刺突蛋白-受体相互作用：机制与治疗机会
Virology. 2025 Jun;607:110507. doi: 10.1016/j.virol.2025.110507. Epub 2025 Mar 21.
3
Phytochemical-based nanosystems: recent advances and emerging application in antiviral photodynamic therapy.

本文引用的文献

1
SARS-CoV-2 omicron spike simulations: broad antibody escape, weakened ACE2 binding, and modest furin cleavage.严重急性呼吸综合征冠状病毒2型奥密克戎毒株刺突蛋白模拟：广泛的抗体逃逸、ACE2结合减弱及适度的弗林蛋白酶切割
Microbiol Spectr. 2023 Aug 31;11(5):e0121322. doi: 10.1128/spectrum.01213-22.
2
Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry.凝血因子直接裂解 SARS-CoV-2 的刺突蛋白并增强病毒进入。
Elife. 2022 Mar 23;11:e77444. doi: 10.7554/eLife.77444.
3
Structural characteristics of Heparan sulfate required for the binding with the virus processing Enzyme Furin.
基于植物化学物质的纳米系统：抗病毒光动力疗法的最新进展与新兴应用
Nanomedicine (Lond). 2025 Feb;20(4):401-416. doi: 10.1080/17435889.2025.2452151. Epub 2025 Jan 23.
4
Chitosan-Based Nanoformulations: Preclinical Investigations, Theranostic Advancements, and Clinical Trial Prospects for Targeting Diverse Pathologies.壳聚糖基纳米制剂：针对多种病理的靶向治疗的临床前研究、治疗学进展和临床试验前景。
AAPS PharmSciTech. 2024 Nov 5;25(8):263. doi: 10.1208/s12249-024-02948-x.
5
Pathogen-binding nanoparticles to inhibit host cell infection by heparan sulfate and sialic acid dependent viruses and protozoan parasites.病原体结合纳米颗粒可抑制硫酸乙酰肝素和唾液酸依赖性病毒及原生动物寄生虫对宿主细胞的感染。
Smart Med. 2024 Mar 1;3(2):e20230046. doi: 10.1002/SMMD.20230046. eCollection 2024 Jun.
6
Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery.用于肺部药物递送的壳聚糖基纳米颗粒的研究进展。
Polymers (Basel). 2023 Sep 21;15(18):3849. doi: 10.3390/polym15183849.
7
Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections.吸入式纳米制剂在呼吸道病毒感染疫苗和治疗中的最新进展。
Pharm Res. 2023 May;40(5):1015-1036. doi: 10.1007/s11095-023-03520-1. Epub 2023 Apr 25.
8
Antiviral polysaccharide and antiviral peptide delivering nanomaterials for prevention and treatment of SARS-CoV-2 caused COVID-19 and other viral diseases.用于预防和治疗由 SARS-CoV-2 引起的 COVID-19 和其他病毒疾病的抗病毒多糖和抗病毒肽递送纳米材料。
J Control Release. 2023 Jun;358:476-497. doi: 10.1016/j.jconrel.2023.05.010. Epub 2023 May 14.
9
Mycolactone: A Broad Spectrum Multitarget Antiviral Active in the Picomolar Range for COVID-19 Prevention and Cure.(mycolactone)：一种广谱多靶点抗病毒化合物，在皮摩尔浓度范围内可有效预防和治疗 COVID-19。
Int J Mol Sci. 2023 Apr 12;24(8):7151. doi: 10.3390/ijms24087151.
10
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.基于蛋白质结构的计算机辅助药物发现方法：针对 COVID-19 治疗的指导。
Mol Aspects Med. 2023 Jun;91:101151. doi: 10.1016/j.mam.2022.101151. Epub 2022 Oct 28.
肝素硫酸盐与病毒加工酶弗林结合所需的结构特征。
Glycoconj J. 2022 Jun;39(3):315-325. doi: 10.1007/s10719-021-10018-8. Epub 2021 Oct 26.
4
Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy.工程化富含棕榈酰化 ACE2 的细胞外囊泡作为 COVID-19 治疗方法。
Adv Mater. 2021 Dec;33(49):e2103471. doi: 10.1002/adma.202103471. Epub 2021 Oct 19.
5
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.德尔塔变异株对英国新冠病毒载量及针对新型严重急性呼吸综合征冠状病毒2感染的疫苗效力的影响。
Nat Med. 2021 Dec;27(12):2127-2135. doi: 10.1038/s41591-021-01548-7. Epub 2021 Oct 14.
6
Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）Delta变异株对亚洲人接种BNT162b2疫苗后产生的抗体中和作用的抗性
Lancet Reg Health West Pac. 2021 Oct;15:100276. doi: 10.1016/j.lanwpc.2021.100276. Epub 2021 Sep 20.
7
Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: A patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion.靶向肺部药物传递在冠状病毒病（COVID-19）治疗中的应用：基于磁性纳米粒子涂层微载体黏附的个体化计算研究。
Int J Pharm. 2021 Nov 20;609:121133. doi: 10.1016/j.ijpharm.2021.121133. Epub 2021 Sep 23.
8
Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.吸入型依度沙班干粉吸入剂制剂：研发、表征及其对 COVID-19 感染相关凝血障碍的影响。
Int J Pharm. 2021 Oct 25;608:121122. doi: 10.1016/j.ijpharm.2021.121122. Epub 2021 Sep 21.
9
Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles.使用工程化的ACE2细胞外囊泡中和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）假病毒
Acta Pharm Sin B. 2022 Mar;12(3):1523-1533. doi: 10.1016/j.apsb.2021.09.004. Epub 2021 Sep 9.
10
Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses.SARS-CoV-2 病毒的德尔塔和德尔塔+变体的进化分析。
J Autoimmun. 2021 Nov;124:102715. doi: 10.1016/j.jaut.2021.102715. Epub 2021 Aug 11.